DSGN

Design Therapeutics, Inc. (DSGN) | Rumor.io

Design Therapeutics

DSGN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,595

Bullish sentiment (50-day avg)100%

Price to earnings ratio-10.1

Market capitalization773.5M

Earnings per share-1.21

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-69.8M

Social

What share of all stock conversation is about DSGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

May 18

Design Therapeutics, Inc. (DSGN) stock fell ~18.5% to $11.71 due to clinical trials sentiment shifting and short-term momentum traders rotating capital out of biotech micro-caps.
The company announced four-week IV data from the RESTORE-FA trial of DT-216P2, demonstrating clinical improvements and comprehensive biomarker activity in Friedreich Ataxia, with a favorable safety profile.
DSGN's stock price dropped 26% on the morning, but some analysts consider the reaction to the data print an overreaction, while others see it as the start of a longer decline.

Generated by AI

Sentiment

Of the messages about DSGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	99.08% +52.02
Bearish	—	—	—	0.92% -52.02

Bullish· Apr 30

The RSI indicator is at 59.02, indicating an overbought condition but also a strong uptrend.
The stock is trading above its 20-day and 50-day moving averages, suggesting a positive trend.
The MACD indicator is at 0.7243, indicating a strong upward momentum.

Bearish· Aug 15

$DSGN is overvalued, worth around $0.50.
The company is burning $20 million per quarter and has a market cap of $122 million, resulting in a 70% haircut.
The asset's negative reaction to a site reaction issue with its Fredreich's ataxia asset, as well as downgrades from SVB Securities and RBC, has led to a 55.39% decline in the pre-market.

Generated by AI

Topics

Of the messages about DSGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	85.71%	65.22%
Technical Analysis	—	—	14.29%	4.64%
Analysts	—	—	0%	29.86%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0.29%

Announcements· Apr 29

$DSGN surges to $16.43 (+28.26%) on distribution deal expansion and pivotal RESTORE-FA trial design with new endpoints, bolstering clinical expertise.
Design Therapeutics, Inc. announces breakthrough R&D milestone with DT-216P2 trial design and endpoints now defined, and new board appointment strengthens clinical expertise.
$DSGN surges to $16.42 (+28.18%) on supply chain partnership news, with strong catalyst driving momentum and high-risk, high-reward setup in play.

Technical Analysis· Apr 29

$DSGN has broken above the $14.20 resistance level with a high volume of 1.34M, confirming institutional accumulation.
The technical target for $DSGN remains at $22.34, with momentum accelerating on the catalyst of the company's RESTORE-FA trial details.
$DSGN has decisively broken above the $14.35 resistance level on a high volume of 1.74M, confirming the breakout with a +31.46% surge to $16.84.

Generated by AI

Community

Of the messages about DSGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	97.14%	22.14%
Newcomers	—	—	2.86%	77.86%

An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different reasons.

1mo agoYahoo Finance

Design Therapeutics posts Q2 loss, updates clinical trials

1mo agoInvesting.com

Design Therapeutics Q2 Net Loss Narrows

Design Therapeutics (DSGN) reported a Q2 net loss late Monday of $0.32 per diluted share, narrowing

1mo agoYahoo Finance

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027

1mo agoBarchart.com

A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN)

2mo agoSeeking Alpha

Also Discussed

Investors talking about DSGN also mention

#	Name	Attention
1	Larimar Therapeutics, Inc.LRMR	0%0
2	EUDA Health Holdings LimitedEUDA	0%new
3	Silicom Ltd.SILC	0%0
4	MKDWELL Tech Inc.MKDW	0%+0
5	LanzaTech Global Inc. Common StockLNZA	0%new
6	Everspin Technologies, Inc.MRAM	0%0
7	Pineapple Financial Inc.PAPL	0%+0
8	Distribution Solutions Group, Inc.DSGR	0%0
9	Avanos Medical Inc.AVNS	0%0
10	Kforce Inc.KFRC	0%0

Design Therapeutics, Inc.

Healthcare
Biotechnology

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases. The company’s current programs target inherited disorders driven by nucleotide repeat expansion mutations, with a portfolio that includes treatments in development for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease. Its approach centers on designing therapeutic candidates that act on the underlying genetic cause of disease rather than only addressing symptoms. Design Therapeutics serves the biotechnology and drug-development market through its proprietary platform, which supports research, preclinical work, and clinical development of novel medicines for patients with high unmet medical needs. The company is headquartered in Carlsbad, California.

Website

Location

6005 Hidden Valley Road

Carlsbad, CA, 92011

United States

Social

What share of all stock conversation is about DSGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

May 18

Design Therapeutics, Inc. (DSGN) stock fell ~18.5% to $11.71 due to clinical trials sentiment shifting and short-term momentum traders rotating capital out of biotech micro-caps.
The company announced four-week IV data from the RESTORE-FA trial of DT-216P2, demonstrating clinical improvements and comprehensive biomarker activity in Friedreich Ataxia, with a favorable safety profile.
DSGN's stock price dropped 26% on the morning, but some analysts consider the reaction to the data print an overreaction, while others see it as the start of a longer decline.

Generated by AI

Sentiment

Of the messages about DSGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	99.08% +52.02
Bearish	—	—	—	0.92% -52.02

Bullish· Apr 30

The RSI indicator is at 59.02, indicating an overbought condition but also a strong uptrend.
The stock is trading above its 20-day and 50-day moving averages, suggesting a positive trend.
The MACD indicator is at 0.7243, indicating a strong upward momentum.

Bearish· Aug 15

$DSGN is overvalued, worth around $0.50.
The company is burning $20 million per quarter and has a market cap of $122 million, resulting in a 70% haircut.
The asset's negative reaction to a site reaction issue with its Fredreich's ataxia asset, as well as downgrades from SVB Securities and RBC, has led to a 55.39% decline in the pre-market.

Generated by AI

Topics

Of the messages about DSGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	85.71%	65.22%
Technical Analysis	—	—	14.29%	4.64%
Analysts	—	—	0%	29.86%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0.29%

Announcements· Apr 29

$DSGN surges to $16.43 (+28.26%) on distribution deal expansion and pivotal RESTORE-FA trial design with new endpoints, bolstering clinical expertise.
Design Therapeutics, Inc. announces breakthrough R&D milestone with DT-216P2 trial design and endpoints now defined, and new board appointment strengthens clinical expertise.
$DSGN surges to $16.42 (+28.18%) on supply chain partnership news, with strong catalyst driving momentum and high-risk, high-reward setup in play.

Technical Analysis· Apr 29

$DSGN has broken above the $14.20 resistance level with a high volume of 1.34M, confirming institutional accumulation.
The technical target for $DSGN remains at $22.34, with momentum accelerating on the catalyst of the company's RESTORE-FA trial details.
$DSGN has decisively broken above the $14.35 resistance level on a high volume of 1.74M, confirming the breakout with a +31.46% surge to $16.84.

Generated by AI

Community

Of the messages about DSGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	97.14%	22.14%
Newcomers	—	—	2.86%	77.86%

Design Therapeutics

Social

May 18

Sentiment

Bullish· Apr 30

Bearish· Aug 15

Topics

Announcements· Apr 29

Technical Analysis· Apr 29

Community

News

Design Therapeutics at Cantor conference: biomarker push takes center stage

Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

Design Therapeutics posts Q2 loss, updates clinical trials

Design Therapeutics Q2 Net Loss Narrows

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN)

Also Discussed

Design Therapeutics, Inc.

Company Information

Location

News

Design Therapeutics at Cantor conference: biomarker push takes center stage

Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

Design Therapeutics posts Q2 loss, updates clinical trials

Design Therapeutics Q2 Net Loss Narrows

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN)

Also Discussed

Social

May 18

Sentiment

Bullish· Apr 30

Bearish· Aug 15

Topics

Announcements· Apr 29

Technical Analysis· Apr 29

Community